Eli Lilly warns compounded tirzepatide mixed with B12 may contain impurities and safety risks as FDA tightens GLP-1 rules—get the latest updates now.

By Leah Douglas WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the main ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Eli Lilly and Co LLY on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide ...

Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

A proposed bill in the Colorado General Assembly bill is aiming to regulate the ingredients used for transparency and safety.

Lilly said it notified the FDA of its findings and called for a nationwide recall of products containing both ingredients ...

Hims & Hers Health has agreed to stop selling compound versions of Wegovy, instead partnering with Novo Nordisk to sell its ...

Hers is currently offering 20% off GLP-1 medication for eligible subscribers who pay over $500 for weight-loss services.

Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established ...

Hims & Hers agrees to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending suit.